Litton Mark James 4
4 · Athira Pharma, Inc. · Filed Mar 4, 2025
Insider Transaction Report
Form 4
Litton Mark James
DirectorPresident and CEO
Transactions
- Award
Stock Option (Right to Buy)
2025-03-03+333,815→ 333,815 totalExercise: $0.38Exp: 2035-03-02→ Common Stock (333,815 underlying) - Award
Restricted Stock Units
2025-03-03+222,543→ 222,543 total→ Common Stock (222,543 underlying)
Footnotes (3)
- [F1]The shares subject to the option shall be scheduled to vest monthly over a term of 48 months on the monthly anniversaries of the grant date, subject to the optionee continuing to be a Service Provider (as defined in the Issuer's 2020 Equity Incentive Plan) through the applicable vesting dates.
- [F2]Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of Issuer's common stock.
- [F3]100% of the RSUs shall vest on the one (1) year anniversary of the grant date, subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2020 Equity Incentive Plan (the "Plan")) through the vesting date.